| Autor: |
Cédric Follonier, Gabriel Rabassa, Mattia Branca, David Carballo, Konstantinos Koskinas, Dik Heg, David Nanchen, Lorenz Räber, Roland Klingenberg, Moa Lina Haller, Sebastian Carballo, Stephan Windecker, Christian M. Matter, Nicolas Rodondi, François Mach, Baris Gencer |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Atherosclerosis Plus, Vol 58, Iss , Pp 1-8 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2667-0895 |
| DOI: |
10.1016/j.athplu.2024.09.002 |
| Popis: |
Background and aims: The 2019 European Society of Cardiology guidelines for the management of dyslipidemia consider the use of high-dose marine omega-3 fatty acid (FA) eicosapentaenoic acid (EPA) supplementation (icosapent ethyl 2 × 2g/day) to lower residual cardiovascular risk in high-risk patients with hypertriglyceridemia. This study aimed to assess the eligibility for omega-3 FA-EPA supplementation in patients with acute coronary syndromes (ACS). Methods: In a prospective Swiss cohort of patients hospitalized for ACS, eligibility for marine omega-3 FA-EPA, defined as plasma triglyceride levels ranging from 1.5 to 5.6 mmol/l, was assessed at baseline and one-year follow-up and compared across subgroups. Lipid-lowering therapy intensification with statin and ezetimibe was modelled to simulate a hypothetical systematic treatment and its effect on omega-3 FA-EPA supplementation eligibility. Results: Of 2643 patients, 98 % were prescribed statin therapy at discharge, including 62 % at a high-intensity regimen; 93 % maintained it after one year, including 53 % at a high-intensity regimen. The use of ezetimibe was 3 % at discharge and 7 % at one year. Eligibility was observed in 32 % (32 % men, 29 % women) one year post-ACS. After modelling systematic treatment with statins, ezetimibe, and both, eligibility decreased to 31 %, 25 % and 24 %, respectively. Eligibility was higher in individuals aged |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
